Tucatinib
CAS 937263-43-9 6 FDA-DMF suppliersSmall Molecule
Overview
Tucatinib is a tyrosine kinase inhibitor used in combination with other drugs to treat HER2-positive breast cancer. It works by blocking the function of the HER2 receptor, effectively slowing the growth of cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Tucatinib expires 26 Apr 2038 and exclusivity 19 Jan 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.